NOIDS.wiki
Calculator
Shop Potency Calculator
Cannabis Science

CBG Benefits: What the Evidence Says About Cannabigerol

Cannabinoid index · Non-intoxicating

Mother cannabinoidNon-intoxicatingNot approvedWADA-prohibited

CBG (cannabigerol) is a non-intoxicating cannabinoid, and most of its claimed benefits rest on lab and animal work. The strongest human evidence is one 2024 trial in 34 healthy adults: a single 20 mg dose lowered self-rated anxiety and stress a little more than placebo, sharpened word recall slightly, and caused no intoxication [3]. Claims for pain, sleep, gut inflammation and bacteria are early signals, not proven effects [2][4].

Specification
Compound
CBG (Cannabigerol)
Acid form
CBGA (cannabigerolic acid), the precursor to the other cannabinoids [1][2]
Classification
Phytocannabinoid (biosynthetic precursor)
CAS number
25654-31-3 [7]
Molecular formula
C21H32O2 [7]
Molecular weight
316 g/mol [7]
Intoxicating
No [3]
Solubility
Fat-soluble; poorly water-soluble

CBG benefits at a glance: what each claim rests on

The table grades each popular claim by the best study behind it. A survey or a mouse study can point the way; only controlled human trials show an effect in people.

Claimed benefitBest evidence so farWhat it showedLevel
Less anxiety and stressRandomised, placebo-controlled trial, 34 adults [3]20 mg CBG lowered self-rated anxiety; stress was lower only at the first checkSmall human trial
MemorySame trial [3]About one more word recalled on one list test; the authors ask for replicationSmall human trial
Pain, sleep, moodOnline survey, 127 users [4]Most users rated their condition much improved; self-report, no control groupSurvey
Gut inflammation (IBD)Mice with induced colitis [5]Less colon inflammationAnimal
Bacteria (MRSA)Lab and mouse studies [2][6]Strong activity against resistant Staphylococcus aureus strainsLab and animal
Brain protectionTwo mouse models of Huntington's disease [2]Signs of protected nerve cellsAnimal

What the human studies found

The 2024 trial is the first controlled test of pure CBG in people. Thirty-four healthy adults, all experienced cannabis users, took a 20 mg hemp-derived CBG tincture and a placebo a week apart, without knowing which was which [3]. CBG lowered self-rated anxiety more than placebo, lowered stress at the first measurement only, and left mood unchanged. Intoxication ratings stayed low, and a phone-based impairment test showed no effect [3]. The authors note the limits themselves: one dose, a small non-clinical sample, and no correction for the number of comparisons [3].

The other human data come from a 2022 survey of 127 people who used CBG-predominant cannabis products [4]. They used it most for anxiety (51.2%), chronic pain (40.9%), depression (33.1%) and sleep problems (30.7%), and most rated their condition much or very much improved. Between 73% and 80% rated it better than conventional medicines for each of those conditions [4]. A survey of self-selected users cannot separate the effect of CBG from expectation, from other cannabinoids in the product, or from the natural course of the condition.

What the lab and animal studies suggest

In cell studies CBG acts on several targets at once. It is a very potent agonist at alpha-2 adrenergic receptors (EC50 0.2 to 72.8 nM), blocks serotonin 5-HT1A receptors (IC50 51.9 nM), and binds the CB1 and CB2 cannabinoid receptors only weakly, with 5 to 27 times less affinity than THC [2]. That profile, rather than CB1 activation, is why it does not intoxicate.

In mice with chemically induced colitis, CBG reduced inflammation of the colon [5]. In the lab it was strongly active against methicillin-resistant Staphylococcus aureus (MRSA) strains [6], and it also cut bacterial counts in infected mice [2]. In two mouse models of Huntington's disease it protected nerve cells [2]. None of these results has yet been repeated in a published human trial.

Side effects and safety

In the 2024 trial, CBG and placebo did not differ on dry mouth, dry eyes, sleepiness, appetite or palpitations [3]. In the survey, 44% of users reported no side effects at all; the most common were dry mouth (16.5%), sleepiness (15%), increased appetite (11.8%) and dry eyes (8.7%) [4].

Pharmacologists add three cautions. Its alpha-2 activity could lower blood pressure and heart rate and dry the mouth; its 5-HT1A blocking may change the effect of drugs that act on serotonin; and CBG oils carry a real risk of drug interactions [2]. CBG is also sold largely outside medicine regulation, and tests of similar CBD products have found labels that did not match the contents [2].

Decarboxylation & infusion

Acid form
CBGA, which the plant converts into THCA, CBDA and CBCA [2]
Decarboxylation
Any remaining CBGA becomes CBG with heat over time
Why it is scarce
Most CBGA is converted before harvest, so CBG is normally present in very low amounts [2]
Infusion
Fat-soluble, so it transfers into oils and butter like the rest

High-CBG material comes from plants with lower activity of the enzymes that convert CBGA [2]. See the decarboxylation temperature chart and CBGA, the acid form.

Evidence & status
Approval status
Not approved as a medicine; sold largely as an unregulated supplement [2]
Strongest support
One small human trial (2024) plus lab and animal studies [2][3]
Competitive sport
Cannabinoids are prohibited in-competition; CBD is the only exception [8]
Lab workAnimal studiesHuman studiesApproved label

Reviewed 2026-10-27. Not legal or medical advice.

What is established, and what is not

Established: CBGA is the compound the plant makes first and turns into THCA, CBDA and CBCA [1][2]; CBG does not intoxicate at the dose tested [3]; it acts on alpha-2, 5-HT1A and other receptors in the lab [2]. Not established: any approved medical use, a long-term safety record, or effects in people beyond one small trial. The marketing claims run ahead of the evidence. For how CBG fits among the other compounds, see what cannabinoids are.

Frequently asked questions

What is CBG good for?

The best human evidence is one 2024 trial in 34 adults, in which a 20 mg dose lowered self-rated anxiety and stress slightly more than placebo and improved word recall a little [3]. Benefits for pain, sleep, gut inflammation and infections come from a user survey and from lab and animal studies, so they are not proven in people [2][4].

Does CBG get you high?

No. In the 2024 trial, intoxication ratings after CBG stayed low and did not differ from placebo, and an impairment test showed no effect [3]. It binds the CB1 receptor only weakly [2].

Can you take CBG every day?

No controlled study has tested daily, long-term CBG use. In a survey of 127 users, the most common side effects were dry mouth (16.5%) and sleepiness (15%) [4]. This page is not dosing advice; anyone taking medicines should ask a doctor or pharmacist first.

Can CBG interact with medication?

It may. Pharmacologists warn of drug interactions with CBG oils and note that its receptor activity could add to the effect of drugs on blood pressure or serotonin [2]. Ask a pharmacist before combining it with any prescription drug.

Is CBG allowed in competitive sport?

No. The WADA Prohibited List bans cannabinoids in-competition, and the only named exception is CBD, so CBG is not exempt [8].

Why is there so little CBG in most cannabis?

Because the plant turns its CBGA into THCA, CBDA and CBCA as it matures, CBG is normally present in very low amounts. High-CBG plants have lower activity of those converting enzymes [2].

Sources

  1. Fellermeier M, Zenk MH. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Letters. 1998;427(2):283-285. PMID 9607329
  2. Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics. 2021;376(2):204-212. doi:10.1124/jpet.120.000340
  3. Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. 2024;14:16163. doi:10.1038/s41598-024-66879-0
  4. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis and Cannabinoid Research. 2022;7(5):706-716. doi:10.1089/can.2021.0058
  5. Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology. 2013;85(9):1306-1316. doi:10.1016/j.bcp.2013.01.017
  6. Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. Journal of Natural Products. 2008;71(8):1427-1430. doi:10.1021/np8002673
  7. SWGDRUG (Scientific Working Group for the Analysis of Seized Drugs). Monograph: Cannabigerol. Revised 22 November 2016. swgdrug.org
  8. NADA Germany. Cannabis and cannabinoids: information sheet on the 2026 WADA Prohibited List. 2026. nada.de

Part of the cannabinoid index. See also CBN.

Educational information about a compound. Not medical advice or guidance on use.

This article is for educational purposes only. Always follow local laws regarding cannabis preparation and use.

Scroll to Top